Implantable Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction: A Single-Institution Retrospective Study

Karis Buford; Haley Eisner; Annah Vollstedt; Brett Friedman; Jason Gilleran; Bernadette M.M. Zwaans; Kenneth M. Peters; Priya Padmanabhan

doi:10.5213/inj.2448144.122

Back

Implantable Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction: A Single-Institution Retrospective Study

Journal article

Open access

Peer reviewed

Implantable Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction: A Single-Institution Retrospective Study

Karis Buford, Haley Eisner, Annah Vollstedt, Brett Friedman, Jason Gilleran, Bernadette M.M. Zwaans, Kenneth M. Peters and Priya Padmanabhan

International neurourology journal, Vol.28(4), pp.278-284

12/31/2024

DOI: 10.5213/inj.2448144.122

PMCID: PMC11710956

PMID: 39765340

Files and links (1)

url

https://doi.org/10.5213/inj.2448144.122View

Published (Version of record) Open Access

Abstract

Purpose: Neurogenic lower urinary tract dysfunction (NLUTD) is highly prevalent among patients with neurologic disorders. Some studies have demonstrated that implantable neuromodulation can improve symptoms of NLUTD. We seek to describe our experience with sacral and pudendal neuromodulation in patients with NLUTD.Methods: A retrospective chart review of patients with “neurogenic bladder” ICD-9/10 (International Classification of Diseases, Ninth Revision/10th Revision) code was performed at a single institution. This included patients from 2008 to 2020 who underwent stage 1 neuromodulation trial. Demographic and clinical information was collected, including neurologic diagnosis, the character of patients’ voiding symptoms, the presence or absence of fecal incontinence, the need for intermittent catheterization, and whether patients had sufficient (>50%) improvement in their symptoms to undergo stage 2 implantable pulse generator (IPG) placement.Results: We identified 82 patients with neurologic diagnoses who underwent stage 1 neuromodulation. The most common diagnoses were diabetic cystopathy (17.07%), spinal surgery (17.07%), and spinal cord injury (12.20%). The most commonly reported symptoms were urinary urgency, and urge urinary incontinence. Overall, 59 patients (71.95%) advanced to stage 2 IPG placement including 72% of patients with sacral leads and 76% with pudendal leads.Conclusions: Neuromodulation is feasible and effective in the treatment of NLUTD. Further investigation into its utilization is warranted.

Neuromodulation

Neurogenic lower urinary tract dysfunction

Neurogenic bladder

Spina bifida

Details

Title: Subtitle: Implantable Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction: A Single-Institution Retrospective Study
Creators: Karis Buford - Beaumont Hospital
Haley Eisner - Beaumont Hospital
Annah Vollstedt - University of Iowa
Brett Friedman - Oakland University
Jason Gilleran - Beaumont Hospital
Bernadette M.M. Zwaans - Beaumont Hospital
Kenneth M. Peters - Beaumont Hospital
Priya Padmanabhan - Beaumont Hospital
Resource Type: Journal article
Publication Details: International neurourology journal, Vol.28(4), pp.278-284
DOI: 10.5213/inj.2448144.122
PMID: 39765340
PMCID: PMC11710956
NLM abbreviation: Int Neurourol J
ISSN: 2093-6931
eISSN: 2093-6931
Publisher: KOREAN CONTINENCE SOC; YEONGOTONG-GU
Number of pages: 7
Language: English
Date published: 12/31/2024
Academic Unit: Urology
Record Identifier: 9984770889402771

Metrics

5 Record Views